#sglt2i — Public Fediverse posts
Live and recent posts from across the Fediverse tagged #sglt2i, aggregated by home.social.
-
When my 14 y/o Twitter account was banned in 2024 after a hack, I lost all #meded posts. But in #slideshare, I found my 2017 presentation, the year after I started my off-label use of #sglt2i in kidney disease. I'm glad I got most things right back then
http://www.slideshare.net/chrisarg/sglt2-inhibitors-in-diabetic-kidney-disease -
When my 14 y/o Twitter account was banned in 2024 after a hack, I lost all #meded posts. But in #slideshare, I found my 2017 presentation, the year after I started my off-label use of #sglt2i in kidney disease. I'm glad I got most things right back then
http://www.slideshare.net/chrisarg/sglt2-inhibitors-in-diabetic-kidney-disease -
When my 14 y/o Twitter account was banned in 2024 after a hack, I lost all #meded posts. But in #slideshare, I found my 2017 presentation, the year after I started my off-label use of #sglt2i in kidney disease. I'm glad I got most things right back then
http://www.slideshare.net/chrisarg/sglt2-inhibitors-in-diabetic-kidney-disease -
When my 14 y/o Twitter account was banned in 2024 after a hack, I lost all #meded posts. But in #slideshare, I found my 2017 presentation, the year after I started my off-label use of #sglt2i in kidney disease. I'm glad I got most things right back then
http://www.slideshare.net/chrisarg/sglt2-inhibitors-in-diabetic-kidney-disease -
When my 14 y/o Twitter account was banned in 2024 after a hack, I lost all #meded posts. But in #slideshare, I found my 2017 presentation, the year after I started my off-label use of #sglt2i in kidney disease. I'm glad I got most things right back then
http://www.slideshare.net/chrisarg/sglt2-inhibitors-in-diabetic-kidney-disease -
When my 14 y/o Twitter account was banned in 2024 after a hack, I lost all #meded posts. But in #slideshare, I found my 2017 presentation, the year after I started my off-label use of #sglt2i in kidney disease. I'm glad I got most things right back then www.slideshare.net/chrisarg/sgl...
-
When my 14 y/o Twitter account was banned in 2024 after a hack, I lost all #meded posts. But in #slideshare, I found my 2017 presentation, the year after I started my off-label use of #sglt2i in kidney disease. I'm glad I got most things right back then www.slideshare.net/chrisarg/sgl...
-
When my 14 y/o Twitter account was banned in 2024 after a hack, I lost all #meded posts. But in #slideshare, I found my 2017 presentation, the year after I started my off-label use of #sglt2i in kidney disease. I'm glad I got most things right back then www.slideshare.net/chrisarg/sgl...
-
Coronary flow reserve increase after 4-year dapagliflozin treatment in patients with type 2 diabetes: the DAPAHEART follow-up study | Cardiovascular Diabetology
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disease associated with a signifi…
#NewsBeep #News #Technology #Angiology #AU #Australia #Cardiology #coronaryarterydisease #Coronaryflowreserve #Dapagliflozin #diabetes #Epicardialadiposetissue #Long-termcoronaryflowreserve #SGLT2i #type2diabetes
https://www.newsbeep.com/au/109264/ -
It seems the usual #EBM suspects are making snarky comments about #CONFIDENCE similar to their comments about #flozins #sglt2i in the years leading up to CREDENCE/DAPA-CKD/EMPA-KIDNEY.
It was obvious then (and it is now) that they don't understand how UACR works as a biomarker -
It seems the usual #EBM suspects are making snarky comments about #CONFIDENCE similar to their comments about #flozins #sglt2i in the years leading up to CREDENCE/DAPA-CKD/EMPA-KIDNEY.
It was obvious then (and it is now) that they don't understand how UACR works as a biomarker -
It seems the usual #EBM suspects are making snarky comments about #CONFIDENCE similar to their comments about #flozins #sglt2i in the years leading up to CREDENCE/DAPA-CKD/EMPA-KIDNEY.
It was obvious then (and it is now) that they don't understand how UACR works as a biomarker -
It seems the usual #EBM suspects are making snarky comments about #CONFIDENCE similar to their comments about #flozins #sglt2i in the years leading up to CREDENCE/DAPA-CKD/EMPA-KIDNEY.
It was obvious then (and it is now) that they don't understand how UACR works as a biomarker -
It seems the usual #EBM suspects are making snarky comments about #CONFIDENCE similar to their comments about #flozins #sglt2i in the years leading up to CREDENCE/DAPA-CKD/EMPA-KIDNEY.
It was obvious then (and it is now) that they don't understand how UACR works as a biomarker -
It seems the usual #EBM suspects are making snarky comments about #CONFIDENCE similar to their comments about #flozins #sglt2i in the years leading up to CREDENCE/DAPA-CKD/EMPA-KIDNEY. It was obvious then (and it is now) that they don't understand how UACR works as a biomarker
-
It seems the usual #EBM suspects are making snarky comments about #CONFIDENCE similar to their comments about #flozins #sglt2i in the years leading up to CREDENCE/DAPA-CKD/EMPA-KIDNEY. It was obvious then (and it is now) that they don't understand how UACR works as a biomarker
-
The results of #confidence were the best news today: combined treatment with #flozin #sglt2i and non steroidal #MRA cut by more than half the level of kidney damage markers (urine albumin/creatinine ratio). In every single trial to date cutting UACR has led to kidney protection
-
The results of #confidence were the best news today: combined treatment with #flozin #sglt2i and non steroidal #MRA cut by more than half the level of kidney damage markers (urine albumin/creatinine ratio). In every single trial to date cutting UACR has led to kidney protection
-
The results of #confidence were the best news today: combined treatment with #flozin #sglt2i and non steroidal #MRA cut by more than half the level of kidney damage markers (urine albumin/creatinine ratio). In every single trial to date cutting UACR has led to kidney protection
-
The results of #confidence were the best news today: combined treatment with #flozin #sglt2i and non steroidal #MRA cut by more than half the level of kidney damage markers (urine albumin/creatinine ratio). In every single trial to date cutting UACR has led to kidney protection
-
The results of #confidence were the best news today: combined treatment with #flozin #sglt2i and non steroidal #MRA cut by more than half the level of kidney damage markers (urine albumin/creatinine ratio). In every single trial to date cutting UACR has led to kidney protection
-
The results of #confidence were the best news today: combined treatment with #flozin #sglt2i and non steroidal #MRA cut by more than half the level of kidney damage markers (urine albumin/creatinine ratio). In every single trial to date cutting UACR has led to kidney protection
-
The results of #confidence were the best news today: combined treatment with #flozin #sglt2i and non steroidal #MRA cut by more than half the level of kidney damage markers (urine albumin/creatinine ratio). In every single trial to date cutting UACR has led to kidney protection
-
The take home point from the long term extension of the #sglt2i #flozin EMPA-KIDNEY trial is that the benefit washes VERY SOON after one stops the drug. www.nejm.org/doi/full/10.... A non-proportional hazards #stats analysis would have shown it directly, but it is also evident in the text
Long-Term Effects of Empaglifl... -
🚨 Big news in ADPKD research!
Two upcoming RCTs on SGLT2i, aiming to extend #SGLT2i benefits to #ADPKD:
🇫🇷 #DAPAPKD, PI @dguerrot & @ecorneclegall: 🎯 Total kidney volume evolution over 2y
🌍 #STOPPKD, PI @MuellerRom, R.Gansevoort, P.Scherrer: 🎯Chronic eGFR slope over 3y🤝 Pooled analysis of 820 patients planned!
-
🚨 Big news in ADPKD research!
Two upcoming RCTs on SGLT2i, aiming to extend #SGLT2i benefits to #ADPKD:
🇫🇷 #DAPAPKD, PI @dguerrot & @ecorneclegall: 🎯 Total kidney volume evolution over 2y
🌍 #STOPPKD, PI @MuellerRom, R.Gansevoort, P.Scherrer: 🎯Chronic eGFR slope over 3y🤝 Pooled analysis of 820 patients planned!
-
🚨 Big news in ADPKD research!
Two upcoming RCTs on SGLT2i, aiming to extend #SGLT2i benefits to #ADPKD:
🇫🇷 #DAPAPKD, PI @dguerrot & @ecorneclegall: 🎯 Total kidney volume evolution over 2y
🌍 #STOPPKD, PI @MuellerRom, R.Gansevoort, P.Scherrer: 🎯Chronic eGFR slope over 3y🤝 Pooled analysis of 820 patients planned!
-
Chronic Kidney Disease in the Older Adult Patient with Diabetes https://www.mdpi.com/2629770
#CKD #Diabetes #FOAMED
Hint: use #flozin #sglt2i #MRA #finerenone #RASi across the age span! -
Chronic Kidney Disease in the Older Adult Patient with Diabetes https://www.mdpi.com/2629770
#CKD #Diabetes #FOAMED
Hint: use #flozin #sglt2i #MRA #finerenone #RASi across the age span! -
Chronic Kidney Disease in the Older Adult Patient with Diabetes https://www.mdpi.com/2629770
#CKD #Diabetes #FOAMED
Hint: use #flozin #sglt2i #MRA #finerenone #RASi across the age span! -
Chronic Kidney Disease in the Older Adult Patient with Diabetes https://www.mdpi.com/2629770
#CKD #Diabetes #FOAMED
Hint: use #flozin #sglt2i #MRA #finerenone #RASi across the age span! -
Chronic Kidney Disease in the Older Adult Patient with Diabetes https://www.mdpi.com/2629770
#CKD #Diabetes #FOAMED
Hint: use #flozin #sglt2i #MRA #finerenone #RASi across the age span! -
Spokane doctor's breakthrough #kidney disease treatment (that would be an aldosterone synthase inhibitor) shows promising results with #flozins / #SGLT2i
https://www.kxly.com/news/spokane-doctors-breakthrough-kidney-disease-treatment-shows-promising-results/article_d6991e6a-a12a-11ee-967a-1b03c9ea2b60.html?utm_medium=social&utm_source=twitter&utm_campaign=user-share via
See release by #Boehringer https://www.boehringer-ingelheim.com/promising-phase-ii-results-chronic-kidney-disease -
Spokane doctor's breakthrough #kidney disease treatment (that would be an aldosterone synthase inhibitor) shows promising results with #flozins / #SGLT2i
https://www.kxly.com/news/spokane-doctors-breakthrough-kidney-disease-treatment-shows-promising-results/article_d6991e6a-a12a-11ee-967a-1b03c9ea2b60.html?utm_medium=social&utm_source=twitter&utm_campaign=user-share via
See release by #Boehringer https://www.boehringer-ingelheim.com/promising-phase-ii-results-chronic-kidney-disease -
Spokane doctor's breakthrough #kidney disease treatment (that would be an aldosterone synthase inhibitor) shows promising results with #flozins / #SGLT2i
https://www.kxly.com/news/spokane-doctors-breakthrough-kidney-disease-treatment-shows-promising-results/article_d6991e6a-a12a-11ee-967a-1b03c9ea2b60.html?utm_medium=social&utm_source=twitter&utm_campaign=user-share via
See release by #Boehringer https://www.boehringer-ingelheim.com/promising-phase-ii-results-chronic-kidney-disease -
Spokane doctor's breakthrough #kidney disease treatment (that would be an aldosterone synthase inhibitor) shows promising results with #flozins / #SGLT2i
https://www.kxly.com/news/spokane-doctors-breakthrough-kidney-disease-treatment-shows-promising-results/article_d6991e6a-a12a-11ee-967a-1b03c9ea2b60.html?utm_medium=social&utm_source=twitter&utm_campaign=user-share via
See release by #Boehringer https://www.boehringer-ingelheim.com/promising-phase-ii-results-chronic-kidney-disease -
Spokane doctor's breakthrough #kidney disease treatment (that would be an aldosterone synthase inhibitor) shows promising results with #flozins / #SGLT2i
https://www.kxly.com/news/spokane-doctors-breakthrough-kidney-disease-treatment-shows-promising-results/article_d6991e6a-a12a-11ee-967a-1b03c9ea2b60.html?utm_medium=social&utm_source=twitter&utm_campaign=user-share via
See release by #Boehringer https://www.boehringer-ingelheim.com/promising-phase-ii-results-chronic-kidney-disease -
Sick day rules and #Flozins
Detailed contrarian review and good discussion of #SGLT2i use during hospitalization https://pubmed.ncbi.nlm.nih.gov/35801339/ (gated)
Given the benefit: the authors suggest continuing Flozins and doing daily glucose + ketones testing
@ChristosArgyrop & @mike_johansen for thoughts?
See their algorithm: -
Sick day rules and #Flozins
Detailed contrarian review and good discussion of #SGLT2i use during hospitalization https://pubmed.ncbi.nlm.nih.gov/35801339/ (gated)
Given the benefit: the authors suggest continuing Flozins and doing daily glucose + ketones testing
@ChristosArgyrop & @mike_johansen for thoughts?
See their algorithm: -
Sick day rules and #Flozins
Detailed contrarian review and good discussion of #SGLT2i use during hospitalization https://pubmed.ncbi.nlm.nih.gov/35801339/ (gated)
Given the benefit: the authors suggest continuing Flozins and doing daily glucose + ketones testing
@ChristosArgyrop & @mike_johansen for thoughts?
See their algorithm: -
Sick day rules and #Flozins
Detailed contrarian review and good discussion of #SGLT2i use during hospitalization https://pubmed.ncbi.nlm.nih.gov/35801339/ (gated)
Given the benefit: the authors suggest continuing Flozins and doing daily glucose + ketones testing
@ChristosArgyrop & @mike_johansen for thoughts?
See their algorithm: -
Sick day rules and #Flozins
Detailed contrarian review and good discussion of #SGLT2i use during hospitalization https://pubmed.ncbi.nlm.nih.gov/35801339/ (gated)
Given the benefit: the authors suggest continuing Flozins and doing daily glucose + ketones testing
@ChristosArgyrop & @mike_johansen for thoughts?
See their algorithm: -
Thanks to all who attended. Follow the link to revisit our #cardiology #bootcamp
#PhysicianAssociate #NursePractitioner #sglt2i #nsMRA #resistantHTN @APAC_Cardiology @brianrosePAS @Lross246 @leyadiel @GiaconaJohn https://www.instagram.com/p/CmwmurbLYUM/?igshid=MDJmNzVkMjY= -
Thanks to all who attended. Follow the link to revisit our #cardiology #bootcamp
#PhysicianAssociate #NursePractitioner #sglt2i #nsMRA #resistantHTN @APAC_Cardiology @brianrosePAS @Lross246 @leyadiel @GiaconaJohn https://www.instagram.com/p/CmwmurbLYUM/?igshid=MDJmNzVkMjY=
